Human Papillomavirus Recombinant Vaccine, Quadrivalent
Pronouncation: (Human pap-i-LOW-ma-VYE-russ Recombinant Vaccine)Class: Vaccine, viral
Trade Names:
Gardasil
- Solution for injection HPV 6 L1 protein 20 mcg, HPV 11 L1 protein 40 mcg, HPV 16 L1 protein 40 mcg, HPV 18 L1 protein 20 mcg per 0.5 mL
Pharmacology
![]() | ||||||
Feedback for Human Papillomavirus Recombinant Vaccine, Quadrivalent
Compare with other drugs. | ||||||
Induces development of humeral immune responses against human papillomavirus (HPV).
Indications and Usage
Prevention of diseases caused by HPV, including cervical cancer, genital warts (condyloma acuminate), and the following precancerous or dysplastic lesions: cervical adenocarcinoma (in situ), cervical intraepithelial neoplasia (grade 2 and 3), vulvar intraepithelial neoplasia (grade 2 and 3), vaginal intraepithelial neoplasia (grade 2 and 3), and cervical intraepithelial neoplasia (grade 1).
Contraindications
Standard considerations.
Dosage and Administration
Women and girls 9 to 26 yr of ageIM 3 separate 0.5 mL doses, with the second dose given 2 mo after the first dose and the third dose given 6 mo after the first dose.
General Advice
- Administer IM in the deltoid region of the upper arm or the higher anterolateral area of the thigh; do not inject intravascularly, subcutaneously, or intradermally.
- The prefilled syringe is for single use only and should not be used for more than 1 individual.
- For single-use vials, a separate sterile syringe and needle must be used for each individual.
- Use the full recommended dose of the vaccine; no dilution or reconstitution is necessary.
- Shake well before using, which will yield a white cloudy liquid.
- Prior to administration, inspect visually for particulate matter and discoloration. Do not use if product has particulates or appears discolored.
Storage/Stability
Store in refrigerator at 36° to 46°F. Do not freeze. Protect from light.
Drug Interactions
Immunosuppressive therapies (eg, alkylating agents, antimetabolites, corticosteroids, cytotoxic drugs, irradiation)Immune responses to vaccines may be reduced.
Laboratory Test Interactions
None well documented.
Adverse Reactions
CNS
Dizziness (4%); insomnia, malaise (1%).
EENT
Nasopharyngitis (6%); nasal congestion (1%).
GI
Nausea (7%); diarrhea (4%); toothache, vomiting (2%).
Local
Pain (84%); erythema, swelling (25%); pruritus (3%).
Musculoskeletal
Myalgia (2%); arthralgia (1%).
Respiratory
Cough, upper respiratory tract infection (2%).
Miscellaneous
Pyrexia (13%).
Precautions
Pregnancy
Category B .
Lactation
Undetermined.
Children
Safety and efficacy not established in children younger than 9 yr of age.
Elderly
Safety and efficacy not established in adults older than 26 yr of age.
Bleeding disorders
When possible, avoid use in individuals with bleeding disorders such as hemophilia or thrombocytopenia, or in individuals receiving anticoagulant therapy.
Impaired immune responsiveness
Reduced antibody response to active immunization may occur in individuals with impaired immune response, whether due to use of immunosuppressive agents, genetic defect, HIV infection, or other causes.
Patient Information
- Inform patient, parent, or guardian that vaccination is not a substitute for routine cervical cancer screening.
- Provide patient, parent, or guardian with required vaccine information with each vaccination.
- Inform patient, parent, or guardian of the benefits and risks associated with vaccination.
- Inform patient, parent, or guardian that use is not recommended during pregnancy.
- Advise patient, parent, or guardian of the importance of completing the immunization series.
- Instruct patient, parent, or guardian to report any adverse reactions to health care provider.
![]() |
Link to Page | ![]() |
Print Page | ![]() |
Email Page | ![]() | Add to List |
Human Papillomavirus Prophylaxis
User Reviews:
0 comment(s) about Human Papillomavirus Recombinant, Quadrivalent








